Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placeme...
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: GlobeNewswire
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport’s shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport. Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel acted as joint book-running managers for the offering. In addition to the shares sold in the initial public offering, Rapport today announced the closing on June 10, 2024, of its sal
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics to Present at Upcoming Epilepsy Medical ConferencesGlobeNewswire
- Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry SummitGlobeNewswire
- Rapport Therapeutics Reports Second Quarter Financials and Provides Business UpdateGlobeNewswire
- Rapport Therapeutics to Present Data for TARP?8 AMPAR Negative Modulator at IASP 2024 World Congress on PainGlobeNewswire
- Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat